Hertfordshire, the UK-based Mylan N.V.'s stock finished Thursday's session 1.10% higher at $37.61 with a total volume of 3.59 million shares traded. Shares of the Company, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide, are trading below its 50-day and 200-day moving averages by 9.84% and 16.42%, respectively. Mylan's stock traded at a PE ratio of 23.91 and has a Relative Strength Index (RSI) of 41.74.
On October 10th, 2016, research firm Raymond James upgraded the Company's stock rating from 'Market Perform' to 'Strong Buy'. Sign up and read the free research report on MYL at: http://stock-callers.com/registration/?symbol=MYL
Horizon Pharma Dublin, Ireland headquartered Horizon Pharma PLC's stock edged 0.90% higher, to close the day at $18.02. The stock recorded a trading volume of 2.01 million shares. Shares of Horizon Pharma, which engages in identifying, developing, acquiring, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the US and internationally, have gained 21.51% in the past one year. The Company's shares are trading 1.54% above its 200-day moving average. Additionally, the stock has an RSI of 41.56. The complimentary research report on HZNP can be downloaded at: http://stock-callers.com/registration/?symbol=HZNP
On Thursday, shares in Dublin, Ireland headquartered Allergan PLC ended the session 1.82% higher at $233.08 with a total volume of 4.37 million shares traded. Shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, are trading 3.04% below its 50-day moving average and 7.28% below its 200-day moving average. Moreover, shares of the Company have an RSI of 45.77.
On October 11th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $305 a share to $299 a share. Register for free on Stock-Callers.com and access the latest report on AGN at: http://stock-callers.com/registration/?symbol=AGN
On Thursday, shares in Somerset, New Jersey headquartered Catalent Inc. recorded a trading volume of 974,643 shares. The stock ended the day 1.66% higher at $24.43. Shares of the Company, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, are trading at a PE ratio of 27.54. Catalent's stock has advanced 0.91% in the previous three months. The Company is trading below its 50-day and 200-day moving averages by 2.78% and 3.02%, respectively. Furthermore, shares of Catalent have an RSI of 43.38.
Yesterday, research firm KeyBanc Capital Markets initiated an 'Overweight' rating on the Company's stock, issuing a target price of $29 per share. Get free access to your research report on CTLT at: http://stock-callers.com/registration/?symbol=CTLT
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA